Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or
Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Does treating a person's cancer based on how they respond to the first course of treatment
be effective while reducing the side effects in patients with Down syndrome?
Basic Study Information
Purpose:Location: University of Rochester
This phase III trial studies response-based chemotherapy in treating newly diagnosed
myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome.
used in chemotherapy work in different ways to stop the growth of cancer cells, either
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Response-based chemotherapy separates patients into different risk groups and treats
according to how they respond to the first course of treatment (Induction I). Response-based
treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome
younger patients with Down syndrome while reducing the side effects.
Lead Researcher (Principal Investigator)
Lead Researcher: Angela Girvin
Study Contact InformationPhone: (585) 275-5830
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search